Introduction：Basic information about CAS 57248-88-1|Pamidronate disodium, including its chemical name, molecular formula, synonyms, physicochemical properties, and safety information, etc.
| Common Name | Pamidronate disodium |
|---|
| CAS Number | 57248-88-1 | Molecular Weight | 281.05 |
|---|
| Density | / | Boiling Point | / |
|---|
| Molecular Formula | C3H11NNa2O7P2 | Melting Point | 300 °C |
|---|
| MSDS | / | Flash Point | / |
|---|
Names
| Name | Disodium Pamidronate Hydrate |
|---|
| Synonym | More Synonyms |
|---|
Pamidronate disodium BiologicalActivity
| Description | Pamidronate disodium, a bisphosphonate drug, can help to strengthen bones.Target: OthersPamidronate belongs to the family of medications known as bisphosphonates. It is used to treat hypercalcemia (high blood calcium) by people who have cancer. Pamidronate is also used to treat cancer that has spread to bones (bone metastases) due to different types of tumours and multiple myeloma (cancer of the bone marrow). Pamidronate is also used to treat the symptoms of Paget's disease of bone. |
|---|
| Related Catalog | Signaling Pathways >>Others >>OthersResearch Areas >>Metabolic Disease |
|---|
| References | [1]. Zarychanski, R., et al., Osteonecrosis of the jaw associated with pamidronate therapy. Am J Hematol, 2006. 81(1): p. 73-5. |
|---|
Chemical & Physical Properties
| Melting Point | 300 °C |
|---|
| Molecular Formula | C3H11NNa2O7P2 |
|---|
| Molecular Weight | 281.05 |
|---|
| PSA | 186.59000 |
|---|
| Appearance of Characters | solid | white |
|---|
| InChIKey | MXOIKYVGQDEWSQ-UHFFFAOYSA-N |
|---|
| SMILES | NCCC(O)(P(=O)(O)O)P(=O)(O)O.[Na] |
|---|
| Storage condition | 2-8°C |
|---|
| Water Solubility | H2O: 28 mg/mL |
|---|
Toxicological Information
CHEMICAL IDENTIFICATION - RTECS NUMBER :
- SZ6525000
- CHEMICAL NAME :
- Phosphonic acid, (3-amino-1-hydroxypropylidene)bis-, disodium salt
- CAS REGISTRY NUMBER :
- 57248-88-1
- LAST UPDATED :
- 199709
- DATA ITEMS CITED :
- 5
- MOLECULAR FORMULA :
- C3-H9-N-O7-P2.2Na
- MOLECULAR WEIGHT :
- 279.05
HEALTH HAZARD DATAACUTE TOXICITY DATA - TYPE OF TEST :
- TDLo - Lowest published toxic dose
- ROUTE OF EXPOSURE :
- Oral
- SPECIES OBSERVED :
- Human - man
- DOSE/DURATION :
- 750 ug/kg/5D-I
- TOXIC EFFECTS :
- Sense Organs and Special Senses (Eye) - visual field changes Sense Organs and Special Senses (Eye) - diplopia Sense Organs and Special Senses (Eye) - effect, not otherwise specified
- REFERENCE :
- ANZJB8 Australian and New Zealand Journal of Medicine. (Modern Medicine of Australia Pty., Ltd., 100 Pacific Highway, North Sydney, 2060, Australia) V.1- 1971- Volume(issue)/page/year: 24,320,1994
- TYPE OF TEST :
- TDLo - Lowest published toxic dose
- ROUTE OF EXPOSURE :
- Intravenous
- SPECIES OBSERVED :
- Human - woman
- DOSE/DURATION :
- 600 ug/kg/6H-C
- TOXIC EFFECTS :
- Nutritional and Gross Metabolic - changes in calcium
- REFERENCE :
- LANCAO Lancet. (7 Adam St., London WC2N 6AD, UK) V.1- 1823- Volume(issue)/page/year: 1,622,1987
- TYPE OF TEST :
- TDLo - Lowest published toxic dose
- ROUTE OF EXPOSURE :
- Intravenous
- SPECIES OBSERVED :
- Human - woman
- DOSE/DURATION :
- 900 ug/kg
- TOXIC EFFECTS :
- Musculoskeletal - joints
- REFERENCE :
- APHRER Annals of Pharmacotherpy. (Harvey Whitney Books Co., POB 42696, Cincinnati, OH 45242) V. 26- 1992- Volume(issue)/page/year: 31,499,1997 ** REPRODUCTIVE DATA **
- TYPE OF TEST :
- TDLo - Lowest published toxic dose
- ROUTE OF EXPOSURE :
- Oral
- DOSE :
- 1740 mg/kg
- SEX/DURATION :
- female 15-22 day(s) after conception lactating female 21 day(s) post-birth
- TOXIC EFFECTS :
- Reproductive - Effects on Newborn - viability index (e.g., # alive at day 4 per # born alive)
- REFERENCE :
- ARZNAD Arzneimittel-Forschung. Drug Research. (Editio Cantor Verlag, Postfach 1255, W-7960 Aulendorf, Fed. Rep. Ger.) V.1- 1951- Volume(issue)/page/year: 42,654,1992
- TYPE OF TEST :
- TDLo - Lowest published toxic dose
- ROUTE OF EXPOSURE :
- Intravenous
- DOSE :
- 60 mg/kg
- SEX/DURATION :
- female 6-15 day(s) after conception
- TOXIC EFFECTS :
- Reproductive - Effects on Embryo or Fetus - fetotoxicity (except death, e.g., stunted fetus) Reproductive - Specific Developmental Abnormalities - musculoskeletal system
- REFERENCE :
- ARZNAD Arzneimittel-Forschung. Drug Research. (Editio Cantor Verlag, Postfach 1255, W-7960 Aulendorf, Fed. Rep. Ger.) V.1- 1951- Volume(issue)/page/year: 42,654,1992
|
Safety Information
| Hazard Codes | Xn |
|---|
| Risk Phrases | R22:Harmful if swallowed. R48:Danger of serious damage to health by prolonged exposure. R41:Risk of serious damage to eyes. R37/38:Irritating to respiratory system and skin . R20/21/22:Harmful by inhalation, in contact with skin and if swallowed . |
|---|
| Safety Phrases | S22:Do not breathe dust . S26:In case of contact with eyes, rinse immediately with plenty of water and seek medical advice . S36/37/39:Wear suitable protective clothing, gloves and eye/face protection . S45:In case of accident or if you feel unwell, seek m |
|---|
| WGK Germany | 3 |
|---|
| RTECS | SZ6525000 |
|---|
| HS Code | 2931900090 |
|---|
Customs
| HS Code | 2931900090 |
|---|
| Summary | 2931900090. other organo-inorganic compounds. VAT:17.0%. Tax rebate rate:13.0%. Supervision conditions:AB(certificate of inspection for goods inward,certificate of inspection for goods outward). MFN tariff:6.5%. General tariff:30.0% |
|---|
Synonyms
| Disodium (3-amino-1-hydroxypropane-1,1-diyl)bis[hydrogen (phosphonate)] |
| Pamidronate disodium salt |
| Pamidronate disodium |
| Phosphonic acid, (3-amino-1-hydroxypropylidene)bis-, sodium salt (1:2) |
| Dinatrium-(3-amino-1-hydroxypropan-1,1-diyl)bis[hydrogen-(phosphonat)] |
| APD |
| Disodium (3-amino-1-hydroxy-1-phosphonopropyl)phosphonate |
| MFCD01938386 |
| EINECS 260-647-1 |
| (3-amino-1-hydroxypropane-1,1-diyl)bis[hydrogène (phosphonate)] de disodium |
| Pamidronate (Disodium) |
